Goldman Sachs Group Inc Merrimack Pharmaceuticals Inc Transaction History

Goldman Sachs Group Inc

$580 Billion
Q2 2024

A detailed history of Goldman Sachs Group Inc transactions in Merrimack Pharmaceuticals Inc stock. As of the latest transaction made, Goldman Sachs Group Inc holds 29,807 shares of MACK stock, worth $450,979. This represents 0.0% of its overall portfolio holdings.

Number of Shares

29,807

Previous 14,471 105.98%

Holding current value

$450,979

Previous $213,000 111.27%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$14.68 - $15.13 $225,132 - $232,033	15,336 Added 105.98%	29,807 $450,000
Q1 2024 May 15, 2024	SELL	$13.06 - $15.0 $270,681 - $310,890	-20,726 Reduced 58.89%	14,471 $213,000
Q4 2023 Feb 13, 2024	BUY	$12.02 - $13.41 $2,932 - $3,272	244 Added 0.7%	35,197 $471,000
Q3 2023 May 14, 2024	SELL	$11.6 - $12.52 $2,830 - $3,054	-244 Reduced 0.69%	34,953 $430,000
Q3 2023 Nov 14, 2023	BUY	$11.6 - $12.52 $241,407 - $260,553	20,811 Added 147.16%	34,953 $430,000
Q2 2023 May 14, 2024	SELL	$12.02 - $13.07 $249,487 - $271,280	-20,756 Reduced 59.48%	14,142 $173,000
Q2 2023 Aug 14, 2023	SELL	$12.02 - $13.07 $249,487 - $271,280	-20,756 Reduced 59.48%	14,142 $173,000
Q1 2023 May 14, 2024	BUY	$11.35 - $12.32 $235,580 - $255,713	20,756 Added 146.77%	34,898 $428,000
Q1 2023 May 11, 2023	BUY	$11.35 - $12.32 $235,580 - $255,713	20,756 Added 146.77%	34,898 $428,000
Q4 2022 Feb 13, 2023	BUY	$3.68 - $12.51 $52,042 - $176,916	14,142 New	14,142 $162,000
Q2 2022 May 14, 2024	SELL	$4.89 - $7.13 $102,958 - $150,122	-21,055 Reduced 59.82%	14,142 $84,000
Q2 2022 Aug 15, 2022	BUY	$4.89 - $7.13 $69,154 - $100,832	14,142 New	14,142 $84,000

Others Institutions Holding MACK

# of Institutions

Shares Held

437K

Call Options Held

Put Options Held

View Full List

About MERRIMACK PHARMACEUTICALS INC

Ticker MACK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 13,410,200
Market Cap $203M
Description
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

More about MACK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc Merrimack Pharmaceuticals Inc Transaction History